Most cancers are malignancies, requiring complex treatment with drugs, chemotherapy, radiation, or surgery. One of the dangerous types of cancer involving the lymph nodes is non-Hodgkin's lymphoma. The treatment of non-Hodgkin's lymphoma is quite complicated, in which immunotherapy has been quite effective, most notably the drug Axicabtagene Cioleucel Suspension.

Rituximab is a brand name drug that belongs to a class of drugs that affect the immune system and fight cancer. The active ingredient in the drug is Rituximab 500 mg. Many doctors recommend against using Rituximab in patients with severe bacterial or fungal infections.

Plerixafor, also known as Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in blood cancer patients. Stem cells are then extracted from the blood and transplanted back into the patient.

Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, and is one of the cancers that has been on the rise in recent years. Early detection of the first signs of the disease will help increase the effectiveness of treatment and prolong the patient's life.

Cancer is a malignant disease, usually it is necessary to screen, detect and treat as early as possible to achieve the highest efficiency. But non-Hodgkin lymphoma will probably be an exception. So can treatment be delayed for non-Hodgkin lymphoma, and if so, how?

How long does non-Hodgkin lymphoma live, and whether non-Hodgkin lymphoma is curable is a concern for many patients and families.

Pathologically, non-Hodgkin lymphoma is a form of lymphoma. So what are the symptoms of non-Hodgkin lymphoma? Non-Hodgkin lymphoma is common in which population?

Skin T-cell lymphoma (CTCL) is a rare type of cancer and starts in white blood cells called T cells (T lymphocytes). In cutaneous T-cell lymphoma, the cancer cells grow abnormally, making it easier for the microflora to attack the skin. So is T-cell skin cancer dangerous? How is this disease treated? Let's find out information about T-cell skin cancer (CTCL) through the article below.